AHCO AdaptHealth (AHCO) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-home health care services · CIK 0001725255
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
107
13F, latest reported quarter
What the filings say about AHCO
Insiders, 180 days
+$162.0K net bought
2 buyers · 1 seller · 0% of sales under a 10b5-1 plan
AdaptHealth insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AdaptHealth Corp. insiders bought a net $162.0K of stock across 100 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (4 buys, 1 sale), the last on Aug 6, 2026.
- +1.7% median (-4.1% mean) 90-day return after 3 previous buys.
- The trade is 58.8% of the 34,000 shares held after it.
- 1 other insider bought within 30 days.
- 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WOLF DALE B bought about $117.2K of AHCO on Aug 7, 2026; 1 other insider bought within 30 days and 107 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 48.4% of the 48,569 shares held after it.
- 1 other insider bought within 30 days.
- 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SAMET KENNETH A bought about $149.9K of AHCO on Aug 6, 2026; 1 other insider bought within 30 days and 107 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on Feb 27, 2026.
- +1.7% median (-4.1% mean) 90-day return after 3 previous buys.
- The trade is 14.0% of the 143,234 shares held after it.
- 1 other insider bought within 30 days.
- 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WOLF DALE B bought about $126.0K of AHCO on Aug 6, 2026; 1 other insider bought within 30 days and 107 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 1, 2026.
- The trade is 9.0% of the 125,263 shares held after it.
- No other insider sold within 30 days.
- 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Schuster III Russell E. sold about $117.7K of AHCO on Jul 1, 2026, the largest insider sale at the company since 2024; 107 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.3% of the 136,538 shares held after it.
- No other insider sold within 30 days.
- 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Schuster III Russell E. sold about $113.4K of AHCO on Jun 1, 2026, the largest insider sale at the company since 2024; 107 funds added in the latest 13F quarter.100 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$162.0K over 180 days
+$393.1K over 90 days
more than 81% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
107 funds bought in last quarter
below 57% of Healthcare Services
Revenue
-0.5% year over year
below 76% of Healthcare Services
Margin
-2.2% net margin
below 53% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
11.9% of the float short (float per yahoo 2026-10-27) · 4.7 days to cover · settled 2026-10-15
more than 76% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AHCO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-36.6%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AHCO: institutional holders (13F)
13F holdings, latest reported quarter
16,312,698 sh
$170.0M
16,061,990 sh
$167.4M
11,477,730 sh
$119.6M
8,580,443 sh
$89.4M
7,882,906 sh
$82.1M
Congress trades in AHCO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AHCO planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Schuster III Russell E.
Filed 2026-07-01
$117.7K
AHCO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Reinhart Genesis PMV Fund
$18.4M position · as of 2026-05-31
2.6%
NORTH SQUARE SMALL CAP VALUE FUND
$3.8M position · as of 2026-05-31
1.8%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.4M position · as of 2026-06-30
1.7%
SBH SMALL CAP VALUE FUND
$5.9M position · as of 2026-06-30
1.3%
NORTH SQUARE KENNEDY MICROCAP FUND
$358.3K position · as of 2026-05-31
1.1%
Invesco S&P SmallCap Value with Momentum ETF
$6.5M position · as of 2026-07-31
1.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $162.0K bought by insiders over 180 days, 107 funds added last quarter. Each figure is a federal filing, dated the day it went public.
AHCO financials
Revenue growth
-0.5%
XBRL, annual
Net margin
-2.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.2B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AHCO
| FY Dec 2025 | $3.2B |
| FY Dec 2024 | $3.3B |
| FY Dec 2023 | $3.2B |
| FY Dec 2022 | $3.0B |
| FY Dec 2021 | $2.5B |
| Jun 2026 | $740.3M |
| Mar 2026 | $819.8M |
| Dec 2025 | $846.3M |
| Sep 2025 | $820.3M |
| Jun 2025 | $800.4M |
| Mar 2025 | $777.9M |
| Dec 2024 | $856.6M |
| Sep 2024 | $805.9M |
At each fiscal year end
Single quarter
Net margin, TTM
-7.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AHCO
| FY Dec 2025 | -2.2% |
| FY Dec 2024 | +2.8% |
| FY Dec 2023 | -21.2% |
| FY Dec 2022 | +2.3% |
| FY Dec 2021 | +6.4% |
| Jun 2026 | -18.1% |
| Mar 2026 | -2.0% |
| Dec 2025 | -12.1% |
| Sep 2025 | +3.0% |
| Jun 2025 | +1.8% |
| Mar 2025 | -0.9% |
| Dec 2024 | +5.9% |
| Sep 2024 | +2.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$97.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AHCO
| FY Dec 2025 | $219.4M |
| FY Dec 2024 | $235.8M |
| FY Dec 2023 | $143.2M |
| FY Dec 2022 | -$17.6M |
| FY Dec 2021 | $72.4M |
| Jun 2026 | -$20.9M |
| Mar 2026 | -$27.5M |
| Dec 2025 | $79.3M |
| Sep 2025 | $66.8M |
| Jun 2025 | $73.3M |
| Mar 2025 | -$58.0K |
| Dec 2024 | $73.1M |
| Sep 2024 | $84.8M |
At each fiscal year end
Single quarter
Debt to equity
1.37x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity AHCO
| FY Dec 2025 | 1.14x |
| FY Dec 2024 | 1.26x |
| FY Dec 2023 | 1.47x |
| FY Dec 2022 | 1.02x |
| FY Dec 2021 | 1.07x |
| Jun 2026 | 1.37x |
| Mar 2026 | 1.21x |
| Dec 2025 | 1.14x |
| Sep 2025 | 1.09x |
| Jun 2025 | 1.14x |
| Mar 2025 | 1.25x |
| Dec 2024 | 1.26x |
| Sep 2024 | 1.34x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.31x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt AHCO
| FY Dec 2025 | 0.35x |
| FY Dec 2024 | 0.27x |
| FY Dec 2023 | 0.22x |
| FY Dec 2022 | 0.17x |
| FY Dec 2021 | 0.13x |
| Jun 2026 | 0.31x |
| Mar 2026 | 0.33x |
| Dec 2025 | 0.35x |
| Sep 2025 | 0.32x |
| Jun 2025 | 0.31x |
| Mar 2025 | 0.30x |
| Dec 2024 | 0.27x |
| Sep 2024 | 0.27x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-15.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AHCO
| FY Dec 2025 | -4.6% |
| FY Dec 2024 | +6.0% |
| FY Dec 2023 | -37.6% |
| FY Dec 2022 | +3.3% |
| FY Dec 2021 | +12.9% |
| Jun 2026 | -15.4% |
| Mar 2026 | -5.2% |
| Dec 2025 | -4.6% |
| Sep 2025 | +5.2% |
| Jun 2025 | +5.2% |
| Mar 2025 | +5.6% |
| Dec 2024 | +6.0% |
| Sep 2024 | -13.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-5.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AHCO
| FY Dec 2025 | -1.6% |
| FY Dec 2024 | +2.0% |
| FY Dec 2023 | -14.0% |
| FY Dec 2022 | +1.3% |
| FY Dec 2021 | +4.4% |
| Jun 2026 | -5.3% |
| Mar 2026 | -1.8% |
| Dec 2025 | -1.6% |
| Sep 2025 | +1.9% |
| Jun 2025 | +1.8% |
| Mar 2025 | +1.9% |
| Dec 2024 | +2.0% |
| Sep 2024 | -4.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital AHCO
| FY Dec 2025 | n/a |
| FY Dec 2024 | +5.3% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +3.3% |
| FY Dec 2021 | +5.5% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +4.1% |
| Jun 2025 | +4.1% |
| Mar 2025 | +4.9% |
| Dec 2024 | +5.3% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed AHCO
| FY Dec 2025 | n/a |
| FY Dec 2024 | +6.7% |
| FY Dec 2023 | -13.7% |
| FY Dec 2022 | +4.0% |
| FY Dec 2021 | +7.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +6.5% |
| Jun 2025 | +6.5% |
| Mar 2025 | +6.0% |
| Dec 2024 | +6.7% |
| Sep 2024 | -1.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing AHCO
| FY Dec 2025 | n/a |
| FY Dec 2024 | 15.87x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 73.92x |
| FY Dec 2021 | 38.22x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 16.27x |
| Jun 2025 | 17.46x |
| Mar 2025 | 19.02x |
| Dec 2024 | 15.87x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.7B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2019-03-31
Enterprise value AHCO
| FY Dec 2025 | $3.1B |
| FY Dec 2024 | $3.3B |
| FY Dec 2023 | $3.1B |
| FY Dec 2022 | $4.8B |
| FY Dec 2021 | $5.4B |
| Jun 2026 | $3.3B |
| Mar 2026 | $3.4B |
| Dec 2025 | $3.1B |
| Sep 2025 | $3.0B |
| Jun 2025 | $3.1B |
| Mar 2025 | $3.4B |
| Dec 2024 | $3.3B |
| Sep 2024 | $3.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+12.2%
TTM free cash flow over market value at close 2026-10-27
FCF yield AHCO
| FY Dec 2025 | +16.3% |
| FY Dec 2024 | +18.4% |
| FY Dec 2023 | +14.4% |
| FY Dec 2022 | -0.7% |
| FY Dec 2021 | +2.2% |
| Jun 2026 | +6.9% |
| Mar 2026 | +11.9% |
| Dec 2025 | +16.3% |
| Sep 2025 | +17.6% |
| Jun 2025 | +18.2% |
| Mar 2025 | +18.8% |
| Dec 2024 | +18.4% |
| Sep 2024 | +15.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing AHCO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.2B | $3.3B | $3.2B | $3.0B |
| Operating income | $90.9M | $263.7M | -$598.4M | $190.4M |
| Net income | -$70.8M | $90.4M | -$678.9M | $69.3M |
| EPS (diluted) | -0.52 | 0.61 | -5.31 | 0.33 |
| Operating cash flow | $601.8M | $541.8M | $480.7M | $373.9M |
| Long-term debt | $1.7B | $2.0B | $2.1B | $2.2B |
| Buybacks | $0 | $0 | $29.3M | $14.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
AHCO Stock Sonar score 6/7 axes
Find similar shapesCompareAHCO ranks highest on insider conviction (84th percentile) and financial health (45th), and lowest on growth (24th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AHCO filings, in plain words
Are AdaptHealth insiders buying or selling AHCO?
In the 180 days to 2026-10-28, AdaptHealth insiders were net buyers, a net $162.0K: $393.1K of purchases and $231.1K of sales reported on Form 4, by 2 buyers and 1 seller.
Read the full summary
In the 180 days to 2026-10-28, AdaptHealth insiders were net buyers of AHCO, a net $162.0K across purchases and sales reported on Form 4 by 2 buyers and 1 seller. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
